GleamWall
中文EN

AKTX Akari Therapeutics Plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1541157 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-86.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-146.3%
ROA-71.8%
ROIC (approx.)-140.0%
Asset turnover—

Leverage & solvency

Liabilities / assets52.2%
Debt / equity0.00x
Current ratio0.48x
Interest coverage-282.65x

Cash quality & payout

Operating cash flow / net income0.44x
Accruals ratio-40.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$2.81M$6.98M
SG&A expense$9.28M$9.66M
Operating income-$17.27M-$21.64M
Interest expense$100,000$244,000
Pretax income-$18.30M-$19.79M
Income tax-$1.00M$0
Net income-$17.30M-$19.79M
EBITDA—-$21.63M
EPS (basic)0.000.00
EPS (diluted)0.000.00
Weighted avg. shares (diluted)67.33B23.89B
Balance sheet
Cash & equivalents$5.20M$2.66M
Current assets$5.46M$2.95M
Goodwill$8.43M$8.43M
Total assets$47.89M$50.56M
Current liabilities$12.35M$19.91M
Total liabilities$19.56M$28.33M
Shareholders' equity$28.33M$22.23M
Shares outstanding90.54B53.19B
Cash flow statement
Operating cash flow-$10.57M-$12.55M
Investing cash flow—$382,000
Financing cash flow$13.17M$10.99M
Depreciation & amortization—$14,000
Stock-based compensation$2.89M$2.25M

Free plan shows the latest 2 periods; Pro shows all 20 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.